Graph Therapeutics - precision immunology
Location: Austria
Investors 2
| Date | Name | Website |
| 02.02.2025 | SquareOne | squareone.... |
| - | Merantix C... | merantix-c... |
Mentions in press and media 7
| Date | Title | Description |
| 24.03.2026 | Umlaut.bio Secures €3 Million, Pioneers Novel Cancer and Autoimmune Therapies | Umlaut.bio secured €3 million in pre-seed funding. The biotech firm targets cancer and inflammatory diseases. It pioneers first-in-biology small molecules. These molecules inhibit tRNA modification synthesis. This novel mechanism prevents w... |
| 16.03.2026 | Ternary Therapeutics targets “undruggable” proteins with AI-designed molecular glues, raising €4.1 million | London-based BioTech startup Ternary Therapeutics has raised €4.1 million (£3.6 million) in Seed funding to scale an AI platform designed to create a new class of medicines known as molecular glues. The round was led by European venture fir... |
| 20.02.2026 | Cancer and immunology player Umlaut.bio adds funding to reach ~€3 million pre-Seed total | Umlaut.bio, a German/Swiss oncology/immunology BioTech company developing tRNA-modifying small molecules, announced the extension of its pre-Seed financing to ~€3 million through the support of BaseLaunch. This addition not only helps to ac... |
| 08.01.2026 | 10 Austrian startups to keep an eye on in 2026 and beyond | Once again, it is that time of the year when we begin our annual series highlighting some of the most promising startups from across Europe. Each edition takes a country-by-country look at the teams and technologies shaping the continent’s ... |
| 12.11.2025 | The UK’s Scripta Therapeutics raises over €10 million to “flip the script” on drug discovery | Oxford BioTech startup Scripta Therapeutics emerges from stealth today by announcing a €10.3 million ($12 million) Seed round to upend conventional approaches to drug discovery. The round is led jointly by Oxford Science Enterprises (OSE) a... |
| 09.01.2025 | AI-powered drug discovery: Graph Therapeutics raises €3 million to tackle inflammatory diseases | Graph Therapeutics, a next-generation biotech company based in Vienna, announced today the closing of a €3 million pre-seed financing round to finance the development of an AI-powered platform to bring the precision medicine paradigm to inf... |
| - | Graph Therapeutics | “Graph Therapeutics” |